Sildenafil

What is Sildenafil? Sildenafil is a highly selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Originally researched as a cardiovascular medication for hypertension and angina pectoris, it was found to have a significant effect on erectile function. In 1998, it became the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED) under the brand name Viagra. It was subsequently approved for the treatment of pulmonary arterial hypertension (PAH) under the brand name Revatio. As a medical milestone, Sildenafil revolutionized the treatment of erectile dysfunction, shifting the therapeutic paradigm from invasive therapies (such as penile injections and implants) to an accessible, oral, on-demand pharmacotherapy. Beyond its reproductive health indications, Sildenafil plays a critical role in pulmonary vascular medicine, providing a targeted vasodilatory effect that reduces pulmonary vascular resistance and improves exercise capacity in patients with PAH. Mechanism of Action The physiological mechanism of penile erection involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP). The increase in cGMP leads to smooth muscle relaxation (vasodilation) in the corpus cavernosum, allowing an inflow of blood and resulting in an erection. Sildenafil does not have a direct relaxant effect on isolated human corpus cavernosum. Instead, it enhances the effect of nitric oxide by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for the degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of nitric oxide, Sildenafil’s inhibition of PDE5 leads to increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. At recommended doses, Sildenafil has no effect in the absence of sexual stimulation. In pulmonary arterial hypertension, Sildenafil acts by inhibiting the PDE5 enzyme in the pulmonary vasculature, where PDE5 is highly expressed. By preventing the degradation of cGMP, Sildenafil promotes nitric oxide-mediated vasodilation of the pulmonary vasculature. This selective dilation of the pulmonary arteries leads to a decrease in pulmonary arterial pressure and pulmonary vascular resistance, easing the workload on the right ventricle of the heart. Pharmacokinetics & Metabolism Sildenafil is rapidly absorbed after oral administration. In the fasting state, absolute bioavailability is approximately 41% (range 25–63%). Maximum observed plasma concentrations (Cmax) are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasting state. When Sildenafil is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. This food interaction is clinically significant, as patients taking the medication on-demand for ED should be advised that a heavy meal may delay the onset of therapeutic action. Sildenafil is widely distributed throughout body tissues, with a mean steady-state volume of distribution (Vss) of 105 liters. Both Sildenafil and its major circulating active metabolite are highly bound to plasma proteins (approximately 96%), and protein binding is independent of total drug concentrations. Sildenafil is metabolized primarily by the cytochrome P450 (CYP) hepatic microsomal enzymes, specifically CYP3A4 (major pathway) and CYP2C9 (minor pathway). The primary circulating metabolite, N-desmethyl sildenafil, is formed by N-demethylation of Sildenafil. This metabolite has a PDE selectivity profile similar to that of Sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. The plasma concentration of this metabolite is approximately 40% of that observed for Sildenafil, accounting for about 20% of Sildenafil's pharmacological effects. The terminal half-life (t1/2) of both Sildenafil and its active N-desmethyl metabolite is approximately 4 hours. Elimination occurs primarily as metabolites, with approximately 80% of the administered oral dose excreted in the feces and approximately 13% excreted in the urine. Sildenafil clearance is reduced in elderly patients (65 years and older), in patients with hepatic impairment (e.g., cirrhosis), and in patients with severe renal impairment (creatinine clearance < 30 mL/min). In these populations, the area under the curve (AUC) for Sildenafil is significantly increased, requiring a lower starting dose (typically 25 mg) to prevent adverse reactions. Therapeutic Indications & Clinical Uses Sildenafil is clinically indicated for two primary medical conditions: Erectile Dysfunction (ED): Sildenafil is used for the treatment of erectile dysfunction, defined as the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. It is effective across a broad spectrum of ED etiologies, including psychogenic, organic (diabetic, cardiovascular, post-prostatectomy), and mixed origin cases. Pulmonary Arterial Hypertension (PAH): Sildenafil is indicated for the treatment of WHO Group 1 pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening, and improve hemodynamic parameters. It is used in both adult and pediatric populations (under specialist guidance) and is formulated for oral and intravenous administration in clinical settings. Raynaud's Phenomenon (Off-Label): Sildenafil is sometimes prescribed off-label for severe, refractory secondary Raynaud's phenomenon. It helps improve peripheral blood flow, reduces the frequency and severity of vasospastic attacks, and facilitates the healing of painful digital ulcers. Dosage & Administration For the treatment of erectile dysfunction, the standard recommended starting dose is 50 mg, taken orally on an empty stomach approximately one hour before anticipated sexual activity. Based on individual efficacy and tolerability, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day. Patients should be informed that the onset of action may be delayed if taken with a high-fat meal. For patients with predisposing factors for drug accumulation—including age over 65, hepatic impairment (Child-Pugh Class A and B), severe renal impairment (CrCl < 30 mL/min), or concurrent use of strong CYP3A4 inhibitors (such as erythromycin, ketoconazole, itraconazole, or ritonavir)—a starting dose of 25 mg should be considered to minimize the risk of dose-related adverse events. For pulmonary arterial hypertension, the standard oral dosage of Revatio (or generic equivalents) is 20 mg taken three times a day, spaced approximately 6 to 8 hours apart, with or without food. Pediatric dosing in PAH is weight-dependent and carefully titrated by pediatric cardiologists or pulmonologists. Contraindications & Drug Interactions Sildenafil is contraindicated in patients with a known hypersensitivity to the drug or any inactive component of the tablet. The most critical contraindication relates to the nitric oxide/cGMP pathway: Nitrates and Nitric Oxide Donors: Sildenafil has been shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using organic nitrates or nitric oxide donors (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or amyl nitrite) in any form, either regularly or intermittently, is strictly contraindicated. Co-administration can lead to a severe, life-threatening drop in blood pressure (hypotension) resulting in syncope, myocardial infarction, or cardiovascular collapse. Guanylate Cyclase Stimulators: Co-administration of Sildenafil with guanylate cyclase stimulators, such as riociguat (used for PAH and chronic thromboembolic pulmonary hypertension), is contraindicated because it may cause symptomatic, severe hypotension. Alpha-Blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers (such as doxazosin, tamsulosin, or terazosin) used for benign prostatic hyperplasia (BPH) or hypertension. In some patients, concomitant use of these two drug classes can lead to symptomatic hypotension or orthostatic syncope. Patients should be hemodynamically stable on alpha-blocker therapy before initiating Sildenafil at the lowest dose of 25 mg. CYP3A4 Inhibitors: Strong inhibitors of the CYP3A4 enzyme, such as ritonavir, ketoconazole, itraconazole, clarithromycin, and telithromycin, significantly increase Sildenafil exposure. The co-administration of Sildenafil with ritonavir is not recommended, and if necessary, should not exceed a maximum single dose of 25 mg of Sildenafil in a 48-hour period. Safety Profile & Adverse Reactions Sildenafil is generally well-tolerated, with most adverse effects being mild to moderate in severity and transient in nature. The safety profile is directly related to its pharmacological action as a vasodilator and its mild cross-reactivity with other phosphodiesterase enzymes (such as PDE6 in the retina). The most common adverse reactions reported in clinical trials (occurring in > 2% of patients) include: Headache: The most frequent side effect, caused by cerebral vasodilation. Flushing: Transient redness and warmth of the face and neck due to cutaneous vasodilation. Dyspepsia: Indigestion caused by relaxation of the lower esophageal sphincter. Nasal Congestion: Congestion resulting from vasodilation of the nasal mucosa. Visual Disturbances: Mild and transient changes in color vision (specifically a blue-green tinge or increased sensitivity to light), caused by mild inhibition of PDE6, which is involved in phototransduction in the retina. Dizziness & Myalgia: Occasional back pain, muscle aches, or lightheadedness. Serious and rare adverse events include priapism (a painful erection lasting longer than 4 hours), which requires immediate medical intervention to prevent permanent damage to erectile tissue. Sudden decrease or loss of vision, which may be a sign of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), and sudden decrease or loss of hearing have been reported in post-marketing surveillance. Patients experiencing sudden vision or hearing changes should discontinue Sildenafil immediately and seek urgent medical care. Frequently Asked Questions How long does it take Sildenafil to work? Sildenafil typically begins to work within 30 to 60 minutes after oral administration. To ensure the fastest onset, it should be taken on an empty stomach. Taking it with a heavy or high-fat meal can delay its effects by an hour or more. Does Sildenafil cause a spontaneous erection? No, Sildenafil does not cause spontaneous erections. It only works in response to sexual stimulation. It facilitates the physiological processes that lead to an erection by enhancing the nitric oxide pathway when a man is sexually aroused. How long does Sildenafil stay in the body? The active effects of Sildenafil generally last for about 4 to 5 hours. After this time, the concentration of the drug in the blood decreases. Most of the drug is eliminated from the body within 24 hours. Can Sildenafil be taken with alcohol? It is recommended to limit or avoid alcohol consumption while taking Sildenafil. Alcohol is a mild vasodilator and can increase the risk of side effects such as dizziness, headache, and orthostatic hypotension, while also impairing the ability to achieve an erection.